ELV LAWSUIT NOTICE: Lose Money on Elevance Health, Inc.? BFA Law Alerts Investors that the Class Action Could Allow Investors to Recover Losses (NYSE:ELV)
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company's senior executives for potential violations of the federal securities laws.
If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc.
Investors have until July 11, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Elevance common stock. The case is pending in the U.S. District Court for the Southern District of Indiana and is captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092.
Why was Elevance Sued for Securities Fraud?
Elevance provides health insurance plans. This includes contracting with states to administer Medicaid benefits. States routinely review Medicaid eligibility, but during COVID, the federal government paused this process. The pause ended in 2023, and states resumed redetermining Medicaid eligibility.
During the relevant period, Elevance represented that it was closely monitoring the cost trends associated with the redetermination process and that the rates Elevance was negotiating were sufficient to address the risk profiles of those patients staying on Medicaid.
As alleged, in truth, the redeterminations caused a significant increase in the acuity and utilization of Elevance's Medicaid members. What's more, the shift occurred to a degree that was not reflected in Elevance's rate negotiations or in its financial guidance for 2024.
The Stock Declines as the Truth is Revealed
On July 17, 2024, Elevance stated that it was now 'expecting second-half utilization to increase in Medicaid' and that it was 'seeing signs of increased utilization across the broader Medicaid population.' On this news, the price of Elevance stock declined $32.21 per share, or nearly 6%, from $553.14 per share on July 16, 2024, to $520.93 per share on July 17, 2024.
Then, on October 17, 2024, Elevance announced its Q3 2024 financial results, revealing that its missed consensus earnings per share ('EPS') expectations by $1.33, or 13.7%, 'due to elevated medical costs in [its] Medicaid business.' On this news, the price of Elevance stock declined $52.61 per share, or nearly 11%, from $496.96 per share on October 16, 2024, to $444.35 per share on October 17, 2024.
Click here if you suffered losses: https://www.bfalaw.com/cases-investigations/elevance-health-inc.
What Can You Do?
If you invested in Elevance you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/elevance-health-inc
Or contact:
Ross Shikowitz
[email protected]
212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/elevance-health-inc
Attorney advertising. Past results do not guarantee future outcomes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
RTX, NOC, and LMT: 3 High Caliber Defense Stocks in a Dangerous Market
While we all hope for a peaceful resolution to the escalating tensions between Israel and Iran—far more important than market movements—the conflict serves as a stark reminder of the strategic value of defense stocks. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter I've written about the defense sector previously, and these picks have performed admirably since then. Let's take a look at three of the top aerospace and defense stocks, Lockheed Martin (LMT), RTX (RTX), and Northrop Grumman (NOC), to see where they stand today. Aerospace and defense companies often offer stable, long-term investment appeal. Their revenues are typically underpinned by multi-year contracts with governments and militaries, providing predictable cash flow. The industry also features high barriers to entry, given the critical nature of the work and the long-standing relationships required to secure contracts—governments are unlikely to entrust vital defense programs to unproven newcomers. Many of these companies are also mature, dividend-paying businesses, making them attractive holdings in uncertain geopolitical environments. RTX Corporation (NYSE:RTX) Formerly known as Raytheon, RTX is one of the largest and most recognizable players in the aerospace and defense sector, with a market capitalization approaching $200 billion. The company was formed through a 2020 merger between Raytheon and United Technologies' aerospace and defense businesses. Today, RTX operates through three major segments. Firstly, Collins Aerospace, a leading provider of advanced aerospace and defense systems, generated $28.3 billion in revenue in 2024. Second, Pratt & Whitney, a leader in aircraft engines and power systems, generated $28.1 billion in revenue in 2024. Lastly, Raytheon, focused on defense technologies including cybersecurity, contributed $26.7 billion last year. With nearly equal revenue distribution across its divisions, RTX is a well-balanced industrial powerhouse. While the U.S. government is its largest customer, RTX also serves global allies, including Poland and the UAE, among others, thereby reinforcing its geopolitical relevance. The stock has gained almost 40% in the past year and now trades at 25x 2025 earnings estimates, slightly above the S&P 500's forward P/E of 21.5, but not excessively priced given the company's scale and stability. RTX also appeals to income investors. It offers a 1.8% dividend yield, modestly higher than the S&P 500's 1.3%, but where it truly stands out is in dividend growth. With 32 consecutive years of dividend increases, RTX has earned its place among Dividend Aristocrats, showcasing a long-standing commitment to returning value to shareholders. Is RTX a Good Stock to Buy? Turning to Wall Street, RTX earns a consensus Moderate Buy rating based on 11 Buys, five Holds, and zero Sell ratings assigned in the past three months. The average analyst RTX stock price target of $138.93 implies 4.7% downside potential from current levels. Northrop Grumman (NYSE:NOC) Formed in 1994 through the acquisition of Grumman Aerospace by Northrop Corporation, Northrop Grumman (NOC) has grown into a $72 billion cornerstone of the aerospace and defense industry. The company produces a wide range of cutting-edge technologies, including advanced weapons, missile defense systems, and aircraft such as the B-21 Raider stealth bomber. It also maintains strong positions in space systems and mission solutions. In 2024, Northrop Grumman reported solid revenue across its diversified business units: Aeronautics ($12 billion), Space Systems ($11.7 billion), Mission Systems ($11.4 billion), and Defense Systems ($8.6 billion). This diverse revenue base highlights the company's broad capabilities and stable income streams. Like RTX, Northrop Grumman maintains a strong international footprint, serving clients in 25 countries, reinforcing its global relevance. The stock currently trades at 20x 2025 earnings estimates, making it cheaper than RTX and slightly below the S&P 500 average, positioning it as a solid, if not flashy, value play for investors. In terms of income, Northrop Grumman matches RTX with a 1.8% dividend yield. More importantly, it's a reliable dividend growth stock, having paid dividends for 35 consecutive years and increased its payout for 21 straight years, underscoring its consistency and shareholder focus. Is Northrop Grumman Stock a Good Buy? Turning to Wall Street, NOC earns a consensus Moderate Buy rating based on 10 Buys, five Holds, and zero Sell ratings assigned in the past three months. The average analyst NOC stock price target of $541.36 implies 9.4% upside potential from current levels. Lockheed Martin (NYSE:LMT) With a market cap of $112 billion, Lockheed Martin (LMT) stands as one of the most established and recognizable names in the aerospace and defense sector. The company is renowned for its iconic military aircraft, including the F-16 Falcon and the F-35 Lightning II, with its Aeronautics segment generating $28.6 billion in revenue in 2024. Lockheed Martin's operations are broad and well-diversified, including Missiles and Fire Control, which generated $12.6 billion in sales for 2024; Rotary and Mission Systems, featuring Sikorsky helicopters and maritime technologies, contributing $17.2 billion; and its Space segment, which brought in $12.4 billion for the year. Altogether, Lockheed Martin reported $71 billion in total revenue for 2024, showcasing the scale and balance of its business. Internationally, Lockheed maintains a robust global presence, working with over 50 countries, including Australia, Germany, Poland, Saudi Arabia, Singapore, and South Korea, which provides meaningful geographic diversification. From a valuation standpoint, Lockheed Martin appears attractive, trading at just 17x 2025 earnings estimates —cheaper than the broader market and the least expensive stock among its peers in this comparison. Income investors will also find Lockheed compelling. With a 2.75% dividend yield, it offers more than double the S&P 500's average and is the highest-yielding stock among prominent U.S. defense names. The company has paid dividends for 29 consecutive years and raised its payout for 22 straight years. With a payout ratio of less than 50%, Lockheed has ample room to continue growing its dividend in the years ahead. Is Lockheed Martin Stock a Buy or Sell? LMT earns a consensus Moderate Buy rating based on seven Buys, eight Holds, and zero Sell ratings assigned in the past three months. The average analyst LMT stock price target of $521.07 implies 11.2% upside potential from current levels. Why Lockheed Martin Stands Out Among Top Defense Stocks I'm bullish on all three of these aerospace and defense stocks, each of which offers a durable business model, long-standing government relationships, diversified revenue streams across multiple segments, reasonable valuations, above-average dividend yields, and impressive records of dividend growth. Among them, I find Lockheed Martin the most compelling, thanks to its lowest valuation and highest dividend yield of the group, alongside a strong track record of consistent dividend increases.
Business Insider
3 hours ago
- Business Insider
TD Securities Remains a Hold on Darden Restaurants (DRI)
TD Securities analyst maintained a Hold rating on Darden Restaurants (DRI – Research Report) yesterday and set a price target of $215.00. The company's shares closed yesterday at $225.78. Confident Investing Starts Here: In addition to TD Securities, Darden Restaurants also received a Hold from Stephens's Jim Salera in a report issued yesterday. However, on the same day, Stifel Nicolaus reiterated a Buy rating on Darden Restaurants (NYSE: DRI). Based on Darden Restaurants' latest earnings release for the quarter ending February 23, the company reported a quarterly revenue of $3.16 billion and a net profit of $323.4 million. In comparison, last year the company earned a revenue of $2.97 billion and had a net profit of $312.9 million Based on the recent corporate insider activity of 80 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DRI in relation to earlier this year. Most recently, in April 2025, Charles Sonsteby, a Director at DRI sold 8,005.00 shares for a total of $1,637,422.75.
Business Insider
3 hours ago
- Business Insider
Guggenheim Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
In a report released yesterday, Seamus Fernandez from Guggenheim maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $936.00. The company's shares closed yesterday at $762.73. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Fernandez is a 5-star analyst with an average return of 12.9% and a 59.46% success rate. Fernandez covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Cidara Therapeutics, and Verve Therapeutics. In addition to Guggenheim, Eli Lilly & Co also received a Buy from Leerink Partners's David Risinger in a report issued on June 18. However, on June 5, Erste Group downgraded Eli Lilly & Co (NYSE: LLY) to a Hold. Based on Eli Lilly & Co's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $12.73 billion and a net profit of $2.76 billion. In comparison, last year the company earned a revenue of $8.77 billion and had a net profit of $2.24 billion
